Last reviewed · How we verify
High-Dose Quadrivalent Influenza Vaccine
A high-dose inactivated influenza vaccine that stimulates a stronger immune response by delivering four times the standard antigen dose to enhance antibody production and cellular immunity against four influenza virus strains.
A high-dose inactivated influenza vaccine that stimulates a stronger immune response by delivering four times the standard antigen dose to enhance antibody production and cellular immunity against four influenza virus strains. Used for Influenza prevention in adults aged 65 years and older, Influenza prevention in immunocompromised adults.
At a glance
| Generic name | High-Dose Quadrivalent Influenza Vaccine |
|---|---|
| Also known as | QIV-HD, Efluelda®, Fluzone® High Dose, Efluelda™ |
| Sponsor | Tor Biering-Sørensen |
| Drug class | Inactivated influenza vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
High-dose quadrivalent influenza vaccine contains increased quantities of hemagglutinin antigens from four influenza virus strains (two A subtypes and two B lineages) compared to standard-dose formulations. The higher antigen load triggers more robust innate and adaptive immune responses, resulting in higher antibody titers and improved protection, particularly in older adults and immunocompromised populations with diminished vaccine responsiveness.
Approved indications
- Influenza prevention in adults aged 65 years and older
- Influenza prevention in immunocompromised adults
Common side effects
- Injection site soreness
- Myalgia
- Fatigue
- Headache
- Low-grade fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: